Period:
Draw Mode:
| Volume | 1,743,863 |
|
|||||
| News | - | ||||||
| Day High | 2.15 | Low High |
|||||
| Day Low | 2.00 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Protalix BioTherapeutics Inc | PLX | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 5.53% | 2.10 | 19:55:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.05 | 2.00 | 2.15 | 2.10 | 1.99 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,147 | 1,743,863 | $ 2.08 | $ 3,627,987 | - | 0.94 - 2.21 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:17:53 | 1 | $ 2.11 | USD |
Protalix BioTherapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 120.50M | 57.38M | 55.54M | $ 47.64M | $ -15.10M | -0.30 | -4.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 110.00k | 8.20% |
Protalix BioTherapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.02 | 2.15 | 1.90 | 1.98 | 1,059,304 | 0.08 | 3.96% |
| 1 Month | 1.80 | 2.21 | 1.74 | 2.00 | 1,334,953 | 0.30 | 16.67% |
| 3 Months | 1.38 | 2.21 | 1.315 | 1.78 | 1,023,290 | 0.72 | 52.17% |
| 6 Months | 1.04 | 2.21 | 1.00 | 1.66 | 581,092 | 1.06 | 101.92% |
| 1 Year | 1.17 | 2.21 | 0.94 | 1.50 | 1,263,738 | 0.93 | 79.49% |
| 3 Years | 2.36 | 7.02 | 0.70 | 2.16 | 897,551 | -0.26 | -11.02% |
| 5 Years | 0.53 | 7.02 | 0.17 | 1.69 | 761,318 | 1.57 | 296.23% |
Protalix BioTherapeutics Description
| Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement. |